Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2011 April 1.
Published in final edited form as:
PMCID: PMC2849007

Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers


Cisplatin is among the most widely used cytotoxic anti-cancer agents in solid tumors, however, the development of secondary resistance remains a major obstacle to clinical efficacy. Treatment-related DNA hypermethylation may play a role in creating drug resistant phenotypes by inactivating genes that are required for cytotoxicity. We applied a pharmacologic unmasking approach to detect hypermethylated genes whose inactivation contributes to cisplatin resistance. Utilizing three pairs of isogeneic, cisplatin-sensitive and -resistant cell lines derived from two parental cell lines (KB-3-1 and SCC25), we identified several hundred genes that were down-regulated in each resistant cell line and re-activated by the DNA methyltransferase inhibitor 5-Aza-2'-deoxycytidine (5-Aza-dC). Among them, 30 genes were common to ≥ 2 cell lines, and/or reported to be down-regulated in previous studies. Bisulfite sequencing confirmed that 14 genes were hypermethylated in resistant cell lines, but not in the sensitive parental cell lines. Six of 14 genes (SAT, C8orf4, LAMB3, TUBB, G0S2, MCAM) were cisplatin-inducible in sensitive, but not in resistant cell lines. siRNA knockdown of two genes, SAT and S100P, increased cell viability with cisplatin treatment in sensitive parental cell lines. S100P knockdown significantly decreased the S-phase fraction (SPF) of parental sensitive cell lines and slowed cell proliferation, which was associated with decreased sensitivity to cisplatin. Based on these findings, we conclude that DNA methylation is a frequent event in cells that are chronically exposed to cisplatin, and that methylation-induced gene silencing may play a role in the development of resistance to cytotoxic chemotherapeutic agents.

Keywords: cisplatin, drug resistance, S100P, methylation, epigenetics


Drug resistance is a major obstacle in cancer chemotherapy. While many solid tumors initially respond to chemotherapeutic drugs, most will recur or progress as a result of acquired drug resistance and the expansion of drug-resistant tumor cell populations (1, 2). Epigenetic alterations, including DNA and histone methylation, play an important role in the initiation and progression of cancer (35). Aberrant DNA methylation at CpG islands is associated with transcriptional repression and abnormal gene silencing (6). In recent years, emerging evidence has also linked epigenetic changes to the development of drug resistance. When compared to sensitive, parental controls, MCF-7/adriamycin resistant tumor cells display DNA hypermethylation and drug resistance that can be reversed by down-regulating DNA methyltransferase genes or by administration of a DNA methylation inhibitor (7). In vivo, 80% of patients enrolled in a Phase II single-arm study in which the mild demethylating agents hydralazine and valproate were added to scheduled chemotherapy showed clinical benefit as well as a reduction in global DNA methylation (8).

While these studies looked at changes in global methylation, there is also evidence that promoter hypermethylation of specific genes with known involvement in drug response may play a role in predicting clinical outcome. Promoter methylation of the DNA-repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) contributes to resistance to the DNA alkylating agent carmustine (BCNU), as well as overall and disease-free survival (9). In primary ovarian tumors, promoter hypermethylation and inactivation of FANCF is associated with acquired cisplatin resistance (10). Finally, tumor DNA isolated from the plasma of patients with ovarian cancer before chemotherapy and at relapse showed that 25% of patients acquired methylation of the DNA mismatch repair protein, hMLH1, and that this was associated with poor overall survival (11).

Despite all these efforts, to date there has been no genome-wide study to systematically investigate methylation of individual genes following exposure to chemotherapy. Our lab has previously described an experimental algorithm that provides knowledge of methylation patterns across a large portion of the genome which has succeeded in identifying novel methylated genes (12). In this study, we applied this algorithm to the study of cisplatin-sensitive and -resistant tumor cell lines in order to identify epigenetically modified genes that are associated with acquired cisplatin resistance.

Materials and Methods

Cell lines

Two cell line pairs, KB-3-1/cisplatin sensitive and KB-3-1/cisplatin resistant (KB-3-1 and KB-CP) and BEL-7404 and 7404-CP20 were kindly provided by Dr. Michael Gottesman (NIH). Genetic fingerprinting of the four cell lines was consistent with the two parental cell lines being of identical origin and the resistant cell lines having been derived from a single parental strain, thus the pairs were subsequently redesignated KB-3-1, KB-CP clone 1 and KB-3-1, KB-CP clone 2. All cell lines were re-verified for their responsiveness to cisplatin treatment by cell viability as described below. The human squamous carcinoma cell lines SCC-25 and its cisplatin-resistant derivative SCC-25/CP were provided by Dr. A. J. Rainbow (McMaster University). All cell lines were grown in DMEM supplemented with 10% fetal bovine serum and penicillin-streptomycin. Media for SCC-25 and SCC-25/CP cells was supplemented with hydrocortisone (0.04 µg/ml) as well. KB-CP resistant cell lines were chronically maintained in media supplemented with cisplatin 5 µg/ml while SCC-25/CP cells are stably cisplatin resistant.

5-Aza-dC treatment of cells

Cells were split to low density (106 per T-75 flask) 24 hours before treatment. Cells were then treated with freshly prepared 5 µM 5-Aza-dC (Sigma-Aldrich, St. Louis, MO) dissolved in 50% acetic acid/50% PBS or were mock treated with the same volume of vehicle (50% acetic acid/50% PBS) in the media for 5 days (media changed on day 3).

RNA extraction and microarray analysis

Total cellular RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. We carried out oligonucleotide microarray analysis using the GeneChip U133A Affymetrix expression microarray containing 22,284 probes and 12K genes following the manufacturer’s directions (Affymetrix, Santa Clara, CA). Signal intensity and statistical significance was established for each transcript using dChip version 2005 ( A 2-fold decrease in signal in each paired sensitive/resistant cell line in combination with 1.5-fold increase after 5Aza-dC treatment (based on the 90% confidence interval of the result and expression minus baseline >50) was used as the statistical cutoff value to identify candidate genes.

RT-PCR and real-time PCR

RNA was reverse transcribed to cDNA using Superscript III (Invitrogen) which was then used as a template for PCR. PCR primers were designed to amplify cDNA fragments approximately 150 to 250 bp in length. Primer sequences are shown in Supplemental Table 1. GAPDH was used as a loading control. For real-time PCR, iTaq SYBR green Supermix with Rox dye (Bio-Rad) was used with the following amplification program for 40 cycles: 95°C for 15 min, 60°C for 1 min. All reactions were performed in duplicate or triplicate, with water controls, and relative quantity was calculated after normalizing to GAPDH expression.

DNA extraction and bisulfite sequencing analysis

Genomic DNA was extracted using standard phenol/chloroform techniques and bisulfite modification of genomic DNA was performed using the Epitect kit (Qiagen) according to the manufacturer’s instructions. The genomic sequence and sequence for 1000 bases upstream of the transcriptions start site (TSS) were obtained from the UCSC genome browser website ( Primer sets were designed to recognize DNA alterations after bisulfite treatment. Bisulfite-treated DNA was amplified for the CpG islands noted to be approximately 500–1000 bases 5′ to the TSS. For genes without defined CpG islands, primers were chosen to cover the most CpG rich sites including the first exon (6). Primer sequences are shown in Supplementary Table 1. All PCR products were gel-extracted or PCR purified (Qiagen) prior to sequencing, and were sequenced using both forward and reverse amplification primers and the ABI BigDye cycle sequencing kit (Applied Biosystems, Foster City, CA).

Methylation specific PCR (MSP)

MSP was performed as described previously (13). MSP primers were designed to match the bisulfite sequencing region. Primer sequences are displayed in Supplementary Table 1. Simultaneous reactions for both unmethylated and methylated primers were performed for 35 cycles using the following conditions: 95°C for 30 sec, 58°C for 1 min, and 72°C for 1 min using platinum Taq (Invitrogen, CA).

TA cloning of SAT promoter region

TA cloning was performed using a TA Cloning® Kit (Invitrogen, CA) following the manufacturer’s instructions. Briefly, bisulfite-treated DNA from KB-3-1 and KB-CP clone 2 cells was amplified using the same primer pairs previously used for bisulfite sequencing of the SAT promoter region. PCR amplicons were gel purified and immediately ligated into a linearized TA cloning vector using T4 DNA ligase at 14 °C overnight. Ligation product (2 µl) was transformed into TOP10 competent cells which were then plated on LB-agar plates coated with X-gal. Following an overnight incubation at 37°C, 10 white clones from each plate were selected for sequencing using T7 primer.

RNAi transfection, cisplatin treatment and viability assay

ON-TARGETplus SMARTpool control siRNA, SAT and S100P siRNA were purchased from Dharmacon (Lafayette, CO) and cells were transfected with RNAiMAX reagent (Invitrogen) according to the manufacturer’s instructions. Briefly, cells were plated at a density of 3000/well in 96-well plates. The following day, a stock solution containing 4 µl (20 µM) of siRNA (control, SAT or S100P) and 6 µl of transfection reagent per 1000 µl of OptiMEM media (Gibco, Carlsbad, CA) was prepared and incubated at room temperature for 20 min. Media was aspirated from each well and replaced with 80 µl of antibiotic-free culture medium (DMEM/10% FBS) plus 20 µl of transfection mixture. Following an overnight incubation, the transfection mixture was replaced with complete culture media. After an additional 24 hrs, cells were treated with cisplatin for 48hrs. Cell viability was subsequently assayed using Calcein AM (Invitrogen). Fluorescence signals generated as a result of Calcein AM cleavage by viable cells were read by a Molecular Devices plate reader (Sunnyvale, CA) using an excitation frequency of 480 nm, and an emission frequency of 535 nm. Each experiment was independently repeated 3 times. A minimum of 6 wells were tested for each cisplatin dose.

Cell growth curve and doubling time

Monolayer cultures were trypsinized to obtain single-cell suspensions. An equal number of approximately 1000 cells were seeded in each well of 96-well plates and a cell proliferation assay was performed for 5 days. Cell number was quantified by calcein AM assay as described above. Cell numbers on day 0 were performed 6 hrs after seeding when the cells had attached to the bottom of the plate, and transfection, when needed, was performed at this time point. Media was changed on day 1 and day 3, and the assay was completed on day 4, when untransfected cells had reached 90–100% confluency. Cell doubling times were calculated as described previously by the Patterson formula (14):

TD=T×log 2(log NTlogN0)

where TD is the population doubling time expressed as hours per doubling, T is days of assay, N0 is the number of cells at time zero, and NT is the cell number on the last day.

Cell cycle analysis

Cell cycle analysis was performed as previously described (15). Cells were plated i n 6-well plates and transfected as described above. Following replacement of transfection media with complete culture media, cells were incubated for 48 hrs and then washed twice with cold PBS, harvested by scraping in PBS, pelleted, and resuspended in 1 ml of hypotonic staining solution containing 1 mg/ml sodium citrate, 3 µl/ml Triton–X 100, 20 µg/ml Ribonuclease A, and 100 µg/ml Propidium iodide. Cell cycle analysis was carried out using a Becton Dickinson FACScan flow cytometer (Franklin Lakes, NJ). Data were analyzed with the Modfit LT software (Verity Software House, Inc., Topsham, ME).

Statistical analysis

The paired Student t-test was used to determine statistical significance. Differences were considered significant at P < 0.05. SigmaStat 3.1 software was used for all statistics (Aspire Software, Ashburn, VA). Results are expressed as mean ± SD, unless otherwise stated.


Pharmacologic unmasking of transcriptionally repressed genes in cisplatin resistant cell lines

Cells were treated with the demethylating agent 5-Aza-dC for 5 days to identify epigenetically inactivated genes associated with the drug-resistant phenotype in the isogeneic cell line pairs, KB-3-1 and KB-CP clones 1 and 2, and SCC-25 and SCC-25/CP. After treatment, changes in gene expression were measured using Affymetrix U133A microarray chips. The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus ( and are accessible through GEO Series record number GSE19397.

We hypothesized that in these cell lines methylation-dependent, sensitivity-associated genes would be expressed in the drug-sensitive parental cell lines, and expression would be silenced or diminished in the drug-resistant daughter cell lines. In addition, we hypothesized that pharmacologic unmasking of promoter hypermethylation would result in re-expression of these genes in the resistant cell lines following 5-Aza-dC treatment. Applying this algorithm, we identified 242 genes in the KB-3-1/KB-CP clone 1 cell lines, 368 genes in the KB-3-1/KB-CP clone 2 cell lines, and 168 genes in the SCC-25/SCC-25/CP cell lines, respectively (Supplementary Fig. 1).

We further screened for genes of interest by identifying those that had diminished expression in at least two of the resistant cell lines tested. Finally, we compared our candidate genes to those reported by other investigators to be down-regulated in platinum-resistant cell lines (Stephen Howell, personal communication, (14, 16, 17)). This approach identified 30 genes that were transcriptionally downregulated in a minimum of two cisplatin-resistant cell lines (Supplementary Fig. 1; Supplementary Table 2). Strikingly, 8 genes from this final list are commonly downregulated in at least four cell lines (C8orf4, CRIP1, CTSB, IGFBP4, MCAM, S100P, SAT1, TUBB2A), with 8 additional genes common to at least 3 cisplatin-resistant cell lines (ADM, C4BPB, CES1, FSTL3, LAMB3, OPN3, PTGS1, RHOB), indicating that downregulation of these genes is frequent across cancer cell lines from different tissue types (Supplementary Table 2).

RT-PCR confirmation of commonly identified genes

Changes in expression of candidate genes were examined by conventional RT-PCR and/or real-time quantitative RT-PCR (Fig. 1; Supplementary Fig. 2). RT-PCR confirmed observed microarray expression changes in at least one cell line screened for 87% of genes examined (25 genes, Fig. 1; Supplementary Table 2; Supplementary Fig. 2). Of note, CDA was highly expressed in KB-3-1 and SCC-25 parental cell lines but was barely detectable in the KB-CP clone 2 and SCC-25/CP resistant cell lines. Treatment with 5-Aza-dC caused a robust re-expression of this gene. Likewise, S100P was highly expressed in KB-3-1 cells, virtually absent in both KB-CP clones, and re-activated after 5-Aza-dC treatment (Fig. 1A). Genes that were confirmed to be downregulated in resistant as compared to sensitive cell lines and concomitantly upregulated after 5-Aza-dC treatment were selected for further study.

Figure 1
RT-PCR and real-time PCR analysis of candidate genes. A, RT was performed on all 3 cell line pairs. For select candidate genes, conventional PCR showed downregulation in the cisplatin-resistant daughter cell lines and re-activation after 5-Aza-dC treatment. ...

Promoter bisulfite sequencing and methylation-specific PCR

In order to confirm promoter hypermethylation in reactivated genes, DNA from parental and daughter cell lines was bisulfite treated, and candidate genes were sequenced using primers designed to encompass a portion of the CpG rich gene promoter region. Additional regions were sequenced whenever a gene demonstrated significant reactivation with 5-Aza-dC but failed to show differential methylation on initial sequencing. Using this approach, we determined that 14 out of 25 genes (54%) were differentially methylated in at least one resistant cell line (Table 1), indicating that methylation occurs during chronic drug treatment and persists in the resistant phenotype.

Table 1
Genes showing cell line-specific methylation in cisplatin-resistant cells

To further confirm the methylation patterns seen with bisulfite sequencing, methylation-specific PCR (MSP) was performed on select candidate genes. Of note, C8orf4 and S100P were unmethylated in parental KB-3-1 cells, but displayed methylation in both resistant cell lines by promoter bisulfite sequencing (Fig. 2A). Consistent with these data, MSP demonstrated unmethylated PCR products in the KB-3-1 parental cell line, while methylated PCR products were present in both KB-CP clone 1 and clone 2 (Fig. 2B). Interestingly, SAT did not display promoter methylation in KB-CP clone 2 cells by sequencing, however, a weak but consistently methylated PCR product was observed by MSP which was absent in the parental KB-3-1 cells (Fig. 2B, arrow). To resolve this discrepancy, TA cloning of the promoter region from KB-CP clone 2 cells was performed and individual clones were sequenced. Of 10 clones sequenced, 2 displayed promoter methylation, indicating that in addition to the promoter methylation seen in SCC-25/CP cells, low level SAT methylation is also present in KB-CP clone 2 cells.

Figure 2
Bisulfite sequencing and methylation-specific PCR (MSP) on candidate genes. A, Direct bisulfite sequencing of gene promoters (C8orf4, S100P, SAT) are presented. Representative sequencing data from either parental or resistant cell lines are shown. For ...

Cisplatin treatment upregulated 6 genes in parental sensitive cells, but not in their resistant counterparts

Since methylation and transcriptional silencing of these genes is associated with the development of cisplatin resistance, we hypothesized that expression of our candidate genes might be modulated by exposure to by cisplatin. To test this theory, all 5 cell lines were exposed to cisplatin (IC50 of sensitive cell lines) or vehicle (DMSO), and RT-PCR was performed to examine the expression level of the 14 methylated genes. Interestingly, 6 genes (43%) were up-regulated by treatment in cisplatin-sensitive, but not the corresponding -resistant cell lines (Fig. 3). These 6 genes are C8orf4, SAT, G0S2, LAMB3, TUBB and MCAM. Thus, nearly half of the methylated, down-regulated candidate genes identified by our algorithm are induced by cisplatin in the sensitive, but not the resistant, cell lines tested.

Figure 3
Cisplatin treatment induces expression of 6 genes in CP-sensitive but not CP-resistant cell lines. Cells were treated with cisplatin (at a dose equivalent to the sensitive cell line’s IC50) or vehicle (DMSO) for 24 hrs. RNA was collected and real-time ...

SAT and S100P siRNA knock-down rendered cells more resistant to cisplatin

To further examine the impact of candidate gene silencing on cisplatin resistance, siRNA duplexes were used to knock down gene expression of 4 genes (C8orf4, CDA, SAT, and S100P) in sensitive cell lines in order to determine if this altered cisplatin cytotoxicity. On initial screening two genes (CDA and C8orf) showed no protective effect (data not shown). However, two others (SAT and S100P) did confer a survival advantage. When transfected cells were subsequently exposed to increasing concentrations of cisplatin for 48 hours, they displayed increased resistance to cisplatin, with better protection being conferred by S100P downregulation in KB-3-1 cells (Fig. 4A for KB-3-1 and 4B for SCC-25; left). Real-time PCR demonstrated that siRNA transfection of KB-3-1, and SCC-25 cells resulted in a nearly 18–23 fold reduction in SAT expression, and a 45-fold reduction in S100P (Fig. 4; right).

Figure 4
siRNA knockdown of SAT and S100P increases parental cell line resistance to cisplatin. KB-3-1 (A) and SCC-25 (B) cell lines were transfected with control, SAT or S100P siRNA duplex nucleotides. Cells were treated with cisplatin for 48hrs, and cell viability ...

Pretreating cisplatin-resistant cells with 5 µM 5-aza-dC for 4 days prior to cisplatin treatment, we found that 5-Aza-dC in the absence of cisplatin induced a significant but mild growth inhibition (13–19%) in all three cell lines by day 6 of treatment (Supplementary Fig. 3A). In part because of this effect, we observed decreased cell viability at all cisplatin doses in pretreated cells. However, after normalizing our results to eliminate 5-Aza-dC’s direct effects on cell growth/survival, we observed an additional, synergetic effect of 5-Aza-dC pretreatment in combination with cisplatin on KB-CP clone 2 and SCC-25/CP cells at cisplatin doses near the IC50 of these cell lines (Supplementary Fig. 3B).

S100P knockdown slowed cell cycle progression and cell proliferation

Since SAT’s role in modulating drug resistance has been reported in detail previously (17, 18), we sought to further examine S100P’s protective effects. Platinum-based drugs are DNA-damaging agents, and as such they generate cell-cycle sensitive toxicity. Hence, downregulation of cell cycling provides a survival advantage in resisting cisplatin. We had previously ascertained that both KB-CP clones demonstrated significantly slower doubling times than their parental cell line. Thus, to test whether this slowing in growth was influenced by S100P expression, we transfected KB-3-1 cells with either control or S100P siRNA and performed a proliferation study for 4 days. Real-time PCR was performed to verify the S100P expression level of cells (Fig. 5A; bottom). Control siRNA transfection had negligible effects on gene expression and cell growth, but S100P knockdown significantly slowed cell growth. S100P knockdown increased doubling time from 1.58 to 2.12 days in KB-3-1 cells (P<0.05). Both KB-CP clones displayed even lower S100P expression than the siRNA transfected parental cells, and their growth rates were even lower (Fig. 5A, 2.2 days for KB-CP clone 1, and 3 days for KB-CP clone 2). In keeping with these data, cell cycle analysis demonstrated a significant drop in S-phase fraction (SPF) in S100P siRNA-transfected KB-3-1 cells compared with cells transfected with control siRNA (Fig. 5B, 17% ± 1.6% vs. 12% ± 0.5%, P<0.05).

Figure 5
S100P knockdown slows cell growth and decreases the S-phase fraction (SPF) of KB-3-1 cells. A, KB-3-1 cells were transfected with S100P siRNA and cell growth rate was assayed on indicated days (top). The growth rate of KB-CP cells (clones 1 and 2) was ...


In this genome-wide methylation study, we provide evidence that methylation of select genes occurs during chronic platinum exposure and can confer drug resistance. Over 50% of genes identified and studied were specifically methylated in at least one resistant cell line. Based on this data, and given the fact that there are hundreds of genes which fit our algorithm in each individual cell line pair, it is reasonable to assume that methylation-induced gene silencing is a frequent and relevant phenomenon during chronic drug exposure. It is also noteworthy that 6 of the 14 methylated genes identified by our selection algorithm are cisplatin inducible. This observation not only suggests their functional relevance to cisplatin cytotoxicity, but also provides a rationale for the methylation-induced silencing of these genes in cells undergoing selection pressure from cisplatin.

While these findings are in keeping with a temporal association between changes in cellular methylation patterns and the development of cisplatin resistance, we have furthered the causal relationship between the two as well by demonstrating that the silencing of two specific genes identified by our algorithm results in increased drug resistance in our cisplatin-sensitive cell lines. One of these genes, SAT, has previously been associated with cisplatin-induced cytotoxicity (17, 1921). In our studies, SAT expression decreased in two resistant cell lines, both with differential promoter methylation. It has been shown that over-expression of SAT makes cells more sensitive to cisplatin (18). Consistent with this finding, we have demonstrated that siRNA-induced gene silencing of SAT in KB-3-1 cells is associated with increased drug resistance. Taken together our data indicate that downregulation of SAT in resistant cell lines plays a role in drug resistance, and that it can be modulated through promoter methylation.

Our data suggest a different role for S100P in the development of cisplatin resistance. S100P, a 95-amino acid protein, can act as an autocrine growth and survival factor (22). S100P displays minimal expression in normal tissue, but expression increases dramatically in some malignancies (2327). This increased expression is associated with demethylation of the S100P gene (28). We and others have observed S100P expression to be drastically decreased (as compared to parental) in at least 5 platinum-resistant cell lines, including two of our cell lines, two bladder cancer cell lines (16), and one colon cancer cell line (14). Thus, we provide the first evidence of S100P re-methylation when cells that express S100P become cisplatin resistant. Although our findings are in vitro, a clinical study of lung cancer patients has shown similar results. Bartling, et al., found S100P mRNA expression to be significantly elevated in lung adenocarcinomas as compared to normal lung tissue. However, this association was not observed in adenocarcinomas from patients who had received neoadjuvant chemotherapy prior to tumor resection (29).

The relationship between slower cell cycle progression and the responsiveness of tumors to chemotherapeutic agents has been widely documented elsewhere. Stewart, et al., suggests that the main factor driving failure of chemotherapy to cure advanced NSCLC is deficiency or saturation of a factor required for cell killing, such as the presence of slow or non-cycling cells (30). Cancer cells survive until therapy cessation by downregulating metabolism/cycling, thus becoming temporarily quiescent and resistant to chemotherapeutic agents (3034). In a study of 184 breast cancer patients treated with primary radiotherapy or neoadjuvant chemotherapy, overall response to neoadjuvant chemotherapy was significantly lower for tumors with low S-phase fraction (SFP) compared with tumors with high SPF (35). Likewise, a study of 81 breast cancer patients found that the response to chemotherapy was significantly better in patients with tumors with high SPF (36). We found in our study that S100P knockdown cells demonstrate slower cell cycle progression, less SPF, and increased resistance to cisplatin. Since the time course of downregulation/remethylation of S100P is within the time frame of the development of resistance, our data suggest that S100P, exerting its effects by regulating cellular proliferation, may be one of the factors that play a role in the failure of multiple cell cycle-sensitive chemotherapy drugs. By utilizing methylation and demethylation to modulate expression of S100P, tumor cells are able to provide themselves with both growth and survival advantages under different circumstances. This regulation through alternating methylation patterns is efficient, fast, and flexible.

It is clear, however, that cisplatin resistance has multiple mechanisms, and that changing S100P expression is not the only factor in the development of this resistance, even in the model described here. Gottesman has previously shown mislocalization of folate-binding protein (37, 38) and cytoskeletal defects including downregulation of the carboplatin-binding proteins, actin and filamin (39) in cisplatin-resistant cell lines. We similarly found downregulation of FOLR1, as well as transcripts for the structural proteins keratin8, laminin, beta 3, and tubulin beta 2A. Interestingly, both laminin beta 3 and tubulin beta 2A displayed promoter methylation in the resistant cell lines. While these genes may play a role in cisplatin resistance, S100P-induced cisplatin-resistance is independent of these structural changes since it can be induced by silencing of the gene in parental cells.

In summary, this study provides evidence that epigenetic promoter methylation is a frequent event during chronic cisplatin exposure, and that secondary changes in gene regulation can play an important role in generating drug-resistant phenotypes. Differentially methylated genes, including those identified in this study, may provide informative drug resistance markers as well as therapeutic targets, potentially leading to improved therapies for cancer patients with better and more durable clinical responses.

Supplementary Material


The expertise, facilities, and instrumentation for Affymetrix GeneChip experimentation and analyses were provided and supported by the Johns Hopkins University Malaria Research Institute.

This work was supported by NCI and NIDCR grants SPORE and EDRN (grant numbers P50 DE019032 and U01 CA084986), and Oncomethylome Sciences.


Conflict of interest: Under a licensing agreement between Oncomethylome Sciences and the Johns Hopkins University, D. Sidransky is entitled to a share of royalties received by the University upon sales of any products described in this article. D. Sidransky owns Oncomethylome Sciences SA stock, which is subject to certain restrictions under University policy. D. Sidransky is a paid consultant to Oncomethylome Sciences SA, and is a paid member of the company's Scientific Advisory Board. The Johns Hopkins University in accordance with its conflict of interest policies is managing the terms of this agreement.


1. Kruh GD. Introduction to resistance to anticancer agents. Oncogene. 2003;22:7262–7264. [PubMed]
2. Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000;59(Suppl 4):9–17. discussion 37-8. [PubMed]
3. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–319. [PubMed]
4. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–124. [PubMed]
5. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28:29–35. [PubMed]
6. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687–692. [PubMed]
7. Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, et al. Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J Transl Med. 2006;4:32. [PMC free article] [PubMed]
8. Candelaria M, Gallardo-Rincon D, Arce C, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007;18:1529–1538. [PubMed]
9. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354. [PubMed]
10. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–574. [PubMed]
11. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420–4426. [PubMed]
12. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2:485–495. [PubMed]
13. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–9826. [PubMed]
14. Tang H, Liu YJ, Liu M, Li X. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs. 2007;18:633–639. [PubMed]
15. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol. 1997;17:4059–4069. [PMC free article] [PubMed]
16. Tsunoda T, Koga H, Yokomizo A, et al. Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene. 2004;24:1396–1402. [PubMed]
17. Allen WL, McLean EG, Boyer J, et al. The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther. 2007;6:128–137. [PubMed]
18. Marverti G, Giuseppina Monti M, Pegg AE, et al. Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin. Carcinogenesis. 2005;26:1677–1686. [PubMed]
19. Hector S, Porter CW, Kramer DL, et al. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther. 2004;3:813–822. [PubMed]
20. Marverti G, Piccinini G, Ghiaroni S, et al. N1,N12-bis(ethyl)spermine effect on growth of cis-diamminedichloroplatinum(II)-sensitive and -resistant human ovarian-carcinoma cell lines. Int J Cancer. 1998;78:33–40. [PubMed]
21. Varma R, Hector S, Greco WR, et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol. 2007;59:711–723. [PubMed]
22. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE) J Biol Chem. 2004;279:5059–5065. [PubMed]
23. Averboukh L, Liang P, Kantoff PW, Pardee AB. Regulation of S100P expression by androgen. Prostate. 1996;29:350–355. [PubMed]
24. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816–824. [PubMed]
25. Fuentes MK, Nigavekar SS, Arumugam T, et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum. 2007;50:1230–1240. [PubMed]
26. Logsdon CD, Simeone DM, Binkley C, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649–2657. [PubMed]
27. Wang G, Platt-Higgins A, Carroll J, et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res. 2006;66:1199–1207. [PubMed]
28. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23:1531–1538. [PubMed]
29. Bartling B, Rehbein G, Schmitt WD, et al. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 2007;43:1935–1943. [PubMed]
30. Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM. Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev. 2007;33:101–137. [PubMed]
31. Marcu L, Bezak E, Olver I, van Doorn T. Tumour resistance to cisplatin: a modelling approach. Phys Med Biol. 2005;50:93–102. [PubMed]
32. Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer. 2005;93:302–309. [PMC free article] [PubMed]
33. Naumov GN, Townson JL, MacDonald IC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003;82:199–206. [PubMed]
34. Siu WY, Arooz T, Poon RY. Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res. 1999;250:131–141. [PubMed]
35. Remvikos Y, Mosseri V, Zajdela A, et al. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy. Ann N Y Acad Sci. 1993;698:193–203. [PubMed]
36. Hietanen P, Blomqvist C, Wasenius VM, et al. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer. 1995;71:1029–1032. [PMC free article] [PubMed]
37. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther. 2007;6:1089–1098. [PubMed]
38. Liang XJ, Shen DW, Garfield S, Gottesman MM. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res. 2003;63:5909–5916. [PubMed]
39. Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer. 2004;91:270–276. [PMC free article] [PubMed]